Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

Marine Natural Products: A Source of Novel Anticancer Drugs

Shaden A. M. Khalifa, Nizar Elias, Mohamed A. Farag and 13 more

Marine Drugs · 2019 · Review · CC BY

doi:10.3390/md17090491

Abstract

Cancer remains one of the most lethal diseases worldwide. There is an urgent need for new drugs with novel modes of action and thus considerable research has been conducted for new anticancer drugs from natural sources, especially plants, microbes and marine organisms. Marine populations represent reservoirs of novel bioactive metabolites with diverse groups of chemical structures. This review highlights the impact of marine organisms, with particular emphasis on marine plants, algae, bacteria, actinomycetes, fungi, sponges and soft corals. Anti-cancer effects of marine natural products in in vitro and in vivo studies were first introduced; their activity in the prevention of tumor formation and the related compound-induced apoptosis and cytotoxicities were tackled. The possible molecular mechanisms behind the biological effects are also presented. The review highlights the diversity of marine organisms, novel chemical structures, and chemical property space. Finally, therapeutic strategies and the present use of marine-derived components, its future direction and limitations are discussed.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Cancer remains one of the most life-threatening diseases worldwide. In 2018, approximately 18 million new cases of cancer reported globally, resulting in approximately 10 million deaths. Figure 1A–C show the estimated new cancer cases of different body tissues, the estimated cancer deaths, and estimated number of new cancer cases in different world areas, respectively. Over 1,000,000 new cases and 65,000 deaths are estimated globally, with an incidence rate around two times higher among men than women. Nonmelanoma skin cancer (NMSC) is the most frequently diagnosed cancer in North America, and in Australia, New Zealand, the countries with the highest incidence rates worldwide in men and women, respectively. The highest incidence rates were reported with increased risk is associated with age, and an unhealthy lifestyle. The incidence of cancer continues to increase due to environmental changes and life style modernization. Lung and breast cancer are the most frequently diagnosed cancers worldwide and are the leading causes of cancer-related death in men and women, respectively. Meanwhile, the predisposition factors of cancer could be both external (tobacco, chemicals, radiation, and infectious organisms), and internal (genetic predispositions, immune conditions).

The progress in biological, immunotherapy and the substantial improvements in modern drug design and manufacturing have made the discovery of a cure for cancer a feasible goal. Cure and prolonged survival have already been achieved for a number of human malignancies, such as lymphomas, testicular cancer, and childhood lymphoblastic leukemia. Despite the significant advances of current therapies, multiple side effects have been reported with chemotherapy, motivating the search for other effective cure with fewer side effects. Natural products represent an available source of new drugs, drug leads and chemical entities. Approximately 80% of the approved chemotherapeutic drugs, and more than half of all drugs are based on bioactive natural products. Eighty-seven percent of human diseases, including cancer, are treated using natural products. Natural bioactive molecules exhibit cytotoxic effects by attacking macromolecules expressed by cancer cells, such as those in oncogenic signal transduction pathways. A significant number of marine-derived metabolites act as antitumor agents via potent growth inhibition of human tumor cells both in vitro, in vivo (in murine) models and in cancer clinical trials. Advanced technology and extensive research on marine natural products have led to the discovery of a new generation of anticancer drugs currently used in clinical trials.

Marine have great potential for discovery of new entities that can aid in the prevention and treatment of cancer. Marine emerged in the late 19th century. After 1980, biotechnology emerged as a field that provided direction to the study of marine, aiming at applications such as drug development. This research is still ongoing using advanced tools. Given the great potential of marine natural product scaffolds, there is an increasing interest for exploiting this diversity and complexity for rational drug discovery. Natural products, in general, have been a prime source of compounds for the treatment of many forms of cancer, and offer a promising opportunity for evaluation of not only new chemical classes of anticancer agents but also novel and potentially relevant mechanisms of action.

2. Nature and Cancer Chemotherapy

Over the past 50 years, emerging evidence has shown that many natural products derived from plants and microbes of marine origin (Table 1), exhibit beneficial effects in the prevention and treatment of cancer, i.e., cytarabine, eribulin mesylate, brentuximab vedotin, and trabectidine are marine-based drugs used against leukemia, metastatic breast cancer, soft tissue sarcoma and ovarian cancer. Not only the marines represent the main source for anticancer drugs but also there are other vital sources like as plants, animals, invertebrates and terrestrial microbes, for example Taxol; is an antineoplastic drug obtained from the bark of the Western Yew tree (Taxus brevifolia L., Taxaceae), proved to be useful in the treatment of breast cancer, in addition to the active complex alkaloid compounds such as Vincristine and Vinblastine which are present in Vinca herb. They have proven effective agents against childhood leukemia and Hodgkin’s disease (a cancer of the lymph nodes), choriocarcinoma, respectively.

Although the National Cancer Institute provides researchers with the resources needed to better elucidate the role of food and nutrients in cancer prevention, cancer chemoprevention using marine natural compounds has not been investigated in-depth and the preclinical and clinical data for this strategy remain scant, in spite of the robust chemical rationale. Many other compounds with anticancer properties have been isolated and developed from various biological resources, such as plants, microbes and marine organisms (Figure 2). Consequently, a large number of natural products are in preclinical investigations, and 13 natural products isolated from marine organisms are being tested in different phases of clinical trials, highlighting the potential of marine natural compounds. A focused, combinatorial approach would has been suggested to accelerate the development of new anti-cancer drugs from marine resources with increased efficiency and fewer side effects.

3. Marine Organisms and Cancer Chemotherapy

Oceans cover over 70% of the earth. The total global biodiversity is estimated to include ca. 500 × 106 species of prokaryotic and eukaryotic organisms. The marine environment is indeed an exceptionally diverse reservoir of life, containing nearly 250,000 described species. Among marine organisms, 3.7 × 1030 microorganisms have been discovered in marine environments, 99% of all bacteria cannot be cultured but can synthesize many fascinating natural products that are potential drug leads. This extraordinary chemical and pharmacological scope of marine organisms could be attributed for the necessity to produce secondary metabolites as defense tools to survive in extreme environments; of temperatures, salinity, pressure and to resist predators.

Since ancient times, marine flora has been used for medicinal purposes worldwide: in India, China, the Near East, and Europe. From then till now, less than 5% of the deep sea has been explored, and less than 0.01% of the deep-sea floor has been sampled in detail. The Caribbean sponge (Cryptotethya crypta) was the first marine organism to be investigated in detail chemically, and extensive phytochemical studies on pure compounds from this organism were performed from 1950 to 1960, before the identification of cytosine arabinoside (ara-C). Furthermore, some marine organisms, such as microflora (bacteria, actinobacteria, cyanobacteria and fungi), microalgae, macroalgae (seaweeds), invertebrate animals sponges, soft corals, sea fans, sea hares, nudibranchs, bryozoans, tunicates, etc., have been investigated for cancer control. The bio-active molecules impact has been evaluated against various cancer types in clinical trials. Additionally, with the ongoing advancement in marine chemistry, new tools have been employed, e.g., metabolomics, to examine marine products from different perspectives.

4. Characterization of Marine Metabolites

The major obstacles for better understanding of marine metabolites chemistry and composition are sampling difficulties. Sufficiently large quantities are required for detailed analyzes and resolution of the instrumental and bioassay approaches used. For modern analytical methods in mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy, sub mg, or low micro gram, amounts may be enough for full structure elucidation. The marine community has used MS for the past three to four decades. A separation method is commonly used together with MS to enhance resolution and selectivity, in hyphenated techniques such as LC-MS, LC-MS/MS, GC-MS, pyrolysis-GC-MS, and direct temperature-resolved MS (DT-MS) methods. MS has been mainly used in past studies for identifying and quantifying the specific fractions or trace components within the marine organisms, and identification is then aided by MS/MS analysis, as exemplified by the identification of hierridin B from a marine cyanobacterium Cyanobium spp. strain. There is no doubt that NMR is the most widely used technique for structural characterization of molecules, i.e., acremines P was isolated from a marine-derived strain of Acremonium persicinum and identified using NMR techniques. Nevertheless, the lower sensitivity level of NMR compared to MS hinders the identification of metabolites present at trace levels or low amounts. Although originally used for small, relatively simple organic compounds, it has gained widespread popularity as a method for marine´s metabolites fingerprinting organism. However, although LC-HRMS is extremely sensitive and can detect compounds present at very low quantities, there are certain classes of compounds that cannot be detected by MS; they may not form ions at all, or ion formation may be suppressed or they are not able to be eluted from the column to be detected. NMR, on the other hand, has no separation step and therefore provides a snapshot of the metabolome of the sample. It is less sensitive than MS, but more robust and reproducible with universal feature in metabolites detection, all of which allowing for comparison of results from different datasets or running at different time periods. Also, coupling of metabolomics to other “omics” technologies, i.e., genomics could aid in better correlation of marine metabolome in relation to its genotype.. These analytical techniques are also used to elucidate the function/mode of action of metabolites. For example, functional metabolomics was employed to reveal metabolic alterations associated in MCF-7 breast cancer cells exposed to the alkaloid ascididemin.

5. From Marine Organisms to Anticancer Drugs

There are more than 22,000 known microbial secondary metabolites, 70% of which are produced by actinomycetes, 20% by fungi, 7% by Bacillus spp. and 1–2% by other bacteria. It should be noted that generally 10% of all currently known biologically active natural products are of microbial origin. There are few examples of marine antineoplastic agents that have reached clinical phase trials. For instance, bryostatin 1, ET-743 and dolastatin 10. The bryostatin 1 has recently entered phase II clinical trial against melanoma, non-Hodgkin’s lymphoma, renal cancer and colorectal cancer. The biological effect of bryostatin 1 is mediated via the promotion of normal growth of bone marrow progenitor cells. Moreover, ET-743, a tetrahydroisoquinilone alkaloid isolated from tunicate Ecteinascidia turbinata entered phase I clinical trials, since it exerts anti-proliferative effects by selective alkylation of guanine residues in the DNA minor groove, whereas dolastatin 10, a member of a peptide family isolated from the mollusk Dolabella auricularia, reached phase II clinical trials, based on its inhibition of microtubule assembly, which eventually leads to metaphase arrest in the cell cycle, (Table 2, Figure 3).

5.1. Marine Plants

Marine plants have rarely been discussed in the literature as a distinct and self-contained group. These plants have traditionally been treated either as the poor relations of marine animals in courses and texts on marine biology or as examples of particular groups of algae, where the essential ‘marine-ness’ of marine plants tends to disappear among the taxonomic and morphological parallels with freshwater algae. Over 90% of marine plant species are algae. Because there is great chemical diversity in marine plants, including marine algae and mangroves, products isolated from these plants have been shown to possess antibacterial, antifungal, analgesic, anti-inflammatory, cytotoxic, hypotensive, and spasmogenic activities.

5.1.1. Macroalgae (Seaweed)

Macroalgae have long been recognized as food, functional food and potential drug sources. Also known as seaweed, multicellular macroalgae contain numerous pharmacologically important bioactive elements to include carotenoids, dietary fiber, protein, essential fatty acids, vitamins (A, B, B12, C, D, E), and minerals such as Ca, P, Na, and K, in addition to polyphenols. An alcoholic extract of the red alga Acanthophora spicifera was supplemented to mice treated with Ehrlich’s ascites carcinoma cells, and to exhibit anti-tumor activity at an oral dose of 100 and 200 mg/kg. Similarly, an extract of the brown seaweed Sargassum thunbergii displayed antitumor activity against transplanted tumor such as sarcoma 180 and Ehrlich solid carcinoma (in vivo). The anti-proliferative effect of fucoidan, isolated from Ascophyllum nodosum was demonstrated against sigmoid colon adenocarcinoma cells (COLO320 DM), in comparison to fibroblasts (hamster kidney fibroblast CCL39). Caulerpenyne from Caulerpa sp. algea attributed to anticancer and antiproliferative effects against neuroblastoma cell line through induction of cells inhibition proliferation with an IC50 of 10 µM. Condriamide-A, isolated from Chondria sp., showed a cytotoxic effect at a dose of 0.5 µg/mL against KB cells and 5 µg/mL against LOVO cells (colon cancer). Two compounds isolated from Cystophora sp., namely, meroterpene and usneoidone, have demonstrated antitumor properties. Sulfated polysaccharides purified from the brown alga Eclonia cava selectively and dose-dependently suppressed the proliferation of murine colon carcinoma (CT-26) and human leukemic monocyte lymphoma (U-937) cell lines. Equally important, stylopoldione, a potent cytotoxic metabolite isolated from Stypodium sp., disrupted mitotic spindle formation functioning via inhibiting synchronous cell division using urchin egg assay (Strongylocentrotus purpuratus Stimpson) at ED50 = 1.1 µg/mL, and to inhibit cells cleavage via inhibition of tubulin polymerization.

5.1.2. Microalgae

Cyanobacteria, also known as blue-green algae, are prolific sources of more than 400 novel metabolites, particularly unique, biologically active peptide and polyketide metabolites, effective at either killing cancer cells by inducing apoptotic death or affecting cell signaling via activation of the protein kinase c family. Approximately half of the 41 screened strains of cyanobacteria exhibited the ability to cause cancer cell death. Two cyanobacteria-derived anti-microtubule agents, i.e., dolastatin 10 and curacin A, have been clinically evaluated for the treatment of cancer and to serve as lead structures for the synthesis of a number of synthetic analogs/derivatives. Calothrixins A and B, are pentacyclic metabolites isolated from Calothrix cyanobacteria with anticancer potent activity against human HeLa cancer cells in a dose-dependent manner at an IC50 of 40 and 350 nM, respectively (in vitro studies). Ulithiacyclamide and patellamide, produced by cyanobacteria Prochloron spp. and Lissoclinum patella, exhibited potent cytotoxic activity against a human nasopharyngeal carcinoma cell line at IC50 value of 17 and 3000 ng/mL, respectively. Borophycin, a boron-containing metabolite isolated from marine cyanobacterial strains of Nostoc linckia and Nostoc spongiaeforme var. tenue, attributed potent cytotoxicity against human epidermoid carcinoma (LOVO) and human colorectal adenocarcinoma (KB) cell lines. Potent cytotoxicity was displayed by cryptophycin 1, isolated from Nostoc sp. GSV 224, against tumor cells in vitro (human tumor cell lines (KB and LOVO with IC50 = 0.005; 0.003 ng/mL)) and in vivo (human solid tumors (colon adenocarcinomas, pancreatic ductal adenocarcinoma and mammary adenocarcinoma). Largazole represented a unique chemical scaffold derived from Symploca spp. with impressive anti-proliferative activity. The parental compound, apratoxin A, isolated from a strain of Lyngbya boulloni, exhibited cytotoxicity against adenocarcinoma. Coibamide A, a promising anti-cancer agent with a new potential mechanism of action, derived from a strain of Leptolyngbya, exhibited significant cytotoxicity against NCIH460 lung and mouse neuro-2a cells (LC50 < 23 nM). Cyanobacteria produce a family of antitumor agents known as cryptophycins, which interfere with tubulin assembly. Scytonemin, is a protein serine/threonine kinase inhibitor of the cell division cycle 25C (cdc25C) in a dose-dependent manner with an IC50 of 2.3 µM where significant inhibition was observed at concentrations as low as 300 nM. Scytonemin is present in the extracellular sheaths of different genera of aquatic and terrestrial blue-green algae. This compound regulates mitotic spindle formation as well as enzyme kinases involved in cell cycle control, and to also inhibit the proliferation of human fibroblasts and endothelial cells. Curacin A, isolated from the organic extracts of Curacao collections of Lyngbya majuscule, is an exceptionally potent anti-proliferative agent that inhibited tubulin polymerization and also exhibited selective inhibitory activity against leukemia and Burkitt lymphoma cell lines (IC50 = 9 nM and 200 nM). Apratoxins represent are another class of cyanobacterial compounds that inhibited a variety of cancer cell lines at nanomolar dose levels.

Various strains of cyanobacteria exhibited apoptotic activity against acute myeloid leukemia cells without affecting non-malignant cells, e.g., hepatocytes and cardiomyoblasts. Based on modern research, cultured benthic cyanobacteria from temperate marine environments provide a promising, under-exploited source for novel drugs against leukemia. Nevertheless, there are some compounds isolated from marine sources, not been yet applied in clinical trials like as calothrixins A, B, ulithiacyclamide, patellamide, borophycin, largazole, etc. This all compound shows anticancer activity against various types of cancer cells with different mechanisms hence we recommend further investigation of their potential biological activities and clinical uses.

5.2. Marine Bacteria

Marine Pseudomonas-derived bioactive substances are diverse and include pyrroles, pseudopeptides, pyrrolidinedione, phloroglucinol, phenazine, benzaldehyde, quinoline, quinolone, phenanthrene, phthalate, andrimid, moiramides, zafrin and bushrin. Some of these bioactive compounds are antimicrobial agents, whereas dibutyl phthalate and di-(2-ethylhexyl) phthalate have been reported to be cathepsin B inhibitors. Discodermolide, bryostatins, sarcodictyin, and eleutherobin are among the most effective anticancer drugs produced mainly by marine bacteria.

In vivo, Lactobacilli and Noctiluca scintillans exhibited chemopreventive effects against colon cancer and melanoma cancer, respectively. Lactobacilli has the ability to reduce the activities of azoreductase, nitroreductase, and β-glucuronidase enzymes in the diet of rats as these dietary components were able to reduce the standard level of enzymes in the intestinal tract thus Lactobacilli suggestive that it could lessen the incidence of colon cancer development. Probiotic bacteria, such as Lactobacilli and Bifidobacteria, produce anticancer substances. The marine-derived Halomonas spp. strain GWS-BW-H8hM was reported to inhibit the growth of HM02 (gastric adenocarcinoma), HepG2 (hepatocellular carcinoma) and MCF7 cell lines to induce apoptosis via cell cycle arrest compared to actinomycin D. Highly heterogeneous polymers, i.e., exopolysaccharides (EPSs) and sulfated EPSs isolated from H. stenophila inhabiting a hypersaline environment have also been reported for their pro-apoptotic effects on T-leukemia cells. Only tumor cells were found susceptible to apoptosis induced by the sulphated EPS (B100S), whilst primary T cells were resistant. The isolation of cytotoxic hydroxyphenylpyrrole dicarboxylic acids, i.e., 3-(4-hydroxyphenyl)-4-phenylpyrrole-2,5-dicarboxylic acid (HPPD-1), 3,4-di-(4-hydroxy-phenyl) pyrrole-2,5-dicarboxylic acid (HPPD-2) and the indole derivatives 3-(hydroxyacetyl)-indole, indole-3-carboxylic acid, indole-3-carboxaldehyde, and indole-3-acetic acid, from a marine Halomonas sp. has also been reported. Both HPPD-1 and HPPD-2 exhibited potent antitumor activities via the inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA) induced activation of Epstein–Barr virus early antigen. The inhibitory effect of HPPD-2 was more potent with respect to HPPD-1 at all tested dose ratios: for instance, 32 nmol (1.1 × 10−2 mg mL−1 in DMSO; 1000% ratio to TPA) of HPPD-2 led to 90% inhibition of TPA-induced activation of EBV-EA (residual activation 10.8%). The two most active extracts were obtained from isolates of Sulfitobacter pontiacus (P1-17B (1E)) and Halomonas axialensis (P5-16B (5E)), that inhibited the growth of HeLa and DU145 cells by 50–70%. The cytotoxic activity observed in isolates P1-37B and P3-37A (Halomonas) could be attributed to the aforementioned cytotoxic compounds from Halomonas spp. extracts prepared from Chromohalobacter salexigens (P3-86A, K-30, P3-86B (2), H. meridian (P3-37B), Idiomarina loihiensis (P3-37C) and C. israelensis (K-18) were found to be the most active at inducing apoptosis in HeLa cells.

5.3. Marine Actinomycetes

Marine actinomycetes include members of the genera Dietzia, Rhodococcus, Streptomyces, Salinispora, and Marinispora. Actinomycetes are undoubtedly the largest producers of secondary metabolites among marine microorganisms. Actinomycete-isolated secondary metabolites account for ca. 45% (~10,000 compounds) of the total known anti-microbial metabolites. Of these actinomycete-derived compounds, 75% were derived from Streptomyce whereas 25% were derived from rare actinomycetes.

Actinomycetes, Streptomyces and Micromonosporaceae are good candidates for the isolation of potent growth-inhibiting compounds and novel antitumor agents. In the exploration of marine-derived actinomycetes as sources of antitumor compounds, lucentamycins A-D, which are 3-methyl-4-ethylideneproline-containing peptides were isolated from Nocardiopsis lucentensis (strain CNR-712). Lucentamycins A and B exhibited significant in vitro cytotoxicity against HCT-116 human colon carcinoma using MTS assay with IC50 = 0.20 and 11 µM, respectively. Thicoraline, a depsipeptide isolated from Micromonospora marina, displayed cytotoxic activity against both LOVO and SW620 human colon cancer cell lines with IC50 of 15 nM and 500 nM, respectively in vitro.

Thiocoraline cytotoxic action was found mediated via an arrest in G1 phase of the cell cycle and a decrease in the rate of S phase progression towards G2/M phases, as assessed using bromodeoxyuridine/DNA biparametric flow cytometric analysis. Trioxacarcins A-C extracted from Streptomyces species showed high anti-tumor activity against lung cell line with IC50 ranging from 0.1, 6.0, 0.003 to 0.26 ng/mL, respectively. Mansouramycin A-D and 3-methyl-7-(methylamino)-5,8-isoquinolinedione, from the marine-derived Mei37 isolate of Streptomyces sp., exhibited significant cytotoxicity with a great degree of selectivity for non-small-cell lung cancer, breast cancer, melanoma, and prostate cancer cells. Macrodiolide tartrolon D, extracted from Streptomyces sp. MDG-04-17-069, exhibited strong cytotoxic activity against three human tumor cell lines, viz., lung (A549), colon (HT29), and breast (MDA-MB-231) cancer (GI50 = 0.16, 0.31 and 0.79 µM) compared to doxorubicin as a standard. Salinosporamide A, another compound isolated from a marine-derived actinomycete, is a highly potent irreversible inhibitor of the 20S proteasome that exhibited selective cytotoxic effect against A-549, HL-60, BEL-7402 and P388 cell lines at IC50 = 0.13, 0.28, 7.5, 35.0 µM, respectively, and was tested in clinical trials as an anticancer agent (Table 2).

5.4. Marine Fungi

Marine-derived fungi represent a rich and promising source of novel anticancer agents. Higher fungi (basidiomycetes), endophytic fungi and filamentous fungi from marine habitats yielded biologically active principal compounds, such as leptosphaerin,, leptosphaerolide (and its O-dihydroquinone derivative), and leptosphaerodione from the lignicolous fungus Leptosphaeria oraemaris (Pleosporaceae). Antioxidative effects against free radical reactions associated with atherosclerosis, dementia, and cancer were exhibited by (I) acremonin A from Acremonium spp., and (II) a xanthone derivative from Wardomyces anomalus. The topo I isomerase inhibitor (+)-3,3,7,7,8,8-hexahydroxy-5,5-dimethylbianthraquinone, isolated from both Aspergillus candidus and A. terreus, showed in vitro cytotoxic and anticancer effects. Aspergiolide A, isolated from the marine filamentous fungus A. glaucus, contributed to the cytotoxicity against the A-549, HL-60, BEL-7402, and P388 cell lines, whereas alkaloids isolated from Penicillium spp. derived from deep-ocean sediment displayed antitumor activities. Two new alkaloids meleagrin analogs, meleagrin D and E, and two new diketopiperazines, roquefortine H and I, showed cytotoxic activity toward A-549 and HL-60 cells via apoptosis and arrested the cell cycle at G2/M phase. The anticancer activity of 14 anthracenedione derivatives of secondary metabolites of the mangrove endophytic fungi Halorosellinia spp. and Guignardia spp. has been reported. The 14 anthracenedione derivatives were found to function via apoptosis induction.

5.5. Marine Sponges

These organisms contributed to nearly 30% of all-natural products discovered to date. The initial discoveries from marine sponges led to the belief that it would not be long before true marine-derived drugs would reach the market. One successful example is the discovery and identification of spongothymidine and spongouridine from the Caribbean sponge Tethya crypta. These compounds were found to possess antiviral activity and synthetic analogs studies eventually led to the development of cytosine arabinoside (AraC) as a clinically anticancer agent. Eribulin, a truncated synthetic version of halichondrin B, derived from the sponge Halichondria okadai, has clinically potential activity against pretreated metastatic breast cancer cells.

5.6. Soft Corals

Sarcophyton is one of the most widely distributed soft coral genera in the tropical and sub-tropical oceans, and approximately 30 species from this genus have been collected and tested for the presence of bioactive secondary metabolites, i.e., fatty acids (arachidonic, eicosapentaenoic, docosahexaenoic acids) that showed cytotoxic activity against brine shrimp in dose-dependent manner (LC50 of 96.7 ppm). Among the most important components of soft coral are cembranoids, which are present at high concentrations (up to 5% dry weight). Cembranoids have an impact on biological activities, i.e., ichthyotoxic, cytotoxic, anti-inflammatory, and antagonistic activity. In vitro cytotoxicity testing showed that furano-cembranoids and decaryiol isolated from Nephthea spp. and Sarcophyton cherbonnieri are effective against several tumor cell lines (gastric epithelial, breast and liver) (with GI50 values ranging from 0.15 to 8.6 µg mL−1) via arrests the cell cycle in the G2/M phase. In addition, crassumolide C isolated for the first time from (the soft coral Lobophytum crissum) was found to inhibit the accumulation of the pro-inflammatory proteins iNOS and COX-2 at 10 µM, as well has a cytotoxic effect toward Ca9-22 cancer cells with IC50 of 1.7 µg mL−1 compared to doxorubicin; appositive control.

6. Bioactive Constituents of Marine Organisms

Polyphenols, polysaccharides, and alkaloids are among the highly active, biologically potent and predominant anticancer compounds isolated from marine organisms.

6.1. Polyphenols

Polyphenols (Figure 4; Table 1), are categorized into phenolic acids, flavonoids, tannins, catechin, anthocyanidins, epigallocatechin, lignin, epicatechin, epigallate, and gallic acid. Polyphenolic compounds are known for their potential to reduce the mitotic index and decrease the levels of cellular proteins needed for cancer cell proliferation and colony formation. For example, scutellarein 4’-methyl ether exhibited anticancer effects in vitro and in vivo due to its cytotoxic activities. In addition to anticancer effects, the phenols exhibited anti-inflammatory activity, antiviral effects, and inhibited the human platelet aggregation. Palmaria palmata, an edible seaweed, is rich in polyphenols with potential antioxidant and anticancer properties. These polyphenols showed metabolic inhibition of xenobiotic-metabolizing enzymes, leading to alteration of the mitotic process in the telophase and thus disruption of cell division.

6.2. Polysaccharides

The other potent group of compounds that is abundantly present in several marine organisms is polysaccharides (Figure 5; Table 1), primarily alginates, agar, and carrageenans. The main mechanism of action of polysaccharides cytotoxic effect is the activation of the innate immune system, leading to attraction of macrophages and natural killer cells to the target site and production of tumoricidal cytokines. A sulfated polysaccharide isolated from a marine Pseudomonas spp. (B-1) filtrate induced apoptosis of human leukaemic cells (U937), whereas pancreatic islet carcinoma apoptosis was observed with PI-88, a sulfated oligosaccharide. Glycosaminoglycans are sulfated internally and thus induced murine melanoma cell apoptosis by altering transcription. Fucoidan, a sulfated polysaccharide (sulfated L-fucose) from the brown algal cell wall, was able to modulate atherosclerosis, angiogenesis, and metastasis, when tested against human lymphoma HS-Sultan cell line. This effect was explained by the consequent activation of caspase-3 and down regulation of the kinase pathway. Fucoidan can disrupt heparansulfate-growth factor/cytokine complexes and act as a substitute for cell surface heparansulfates by stabilizing the interaction between growth factors and their receptors.

6.3. Alkaloids

Alkaloids derived of marine origin are divided into four groups, namely, indoles, halogenated indoles phenylethylamines, and other alkaloids (Figure 6; Table 1), most of which belong to phenylethylamines and indoles. Two derivatives, namely, lophocladine A and lophocladine B, have been isolated from the red alga Lophocladia spp.. Similarly, the presence of alkaloids, e.g., acanthicifolin, brugine and benzoquinones, in Acanthus illicifolius, Bruguiera sexangula, and Kandelia candel has been reported. “Rhizophrine” is a major alkaloid constituent of the leaves of Rhizophora mucronata and R. stylosa, species of mangrove found on coasts and river banks in East Africa and the Indo-Pacific region. The growth inhibitory activity of these compounds has been successfully demonstrated using various cancer cell lines.

6.4. Peptides

Different types of peptides (Figure 7; Table 1), have been isolated from a wide variety of marine flora. In the last decade, ca. 2500 new peptides with anti-proliferative activity have been identified. Purified peptides have exhibited cytotoxic effects against various human cell lines, including pancreatic, breast, bladder and lung cell lines. Apratoxin A, a cyclic depsipeptide, exerted cytotoxic effects against human HeLa cervical carcinoma cells via cell cycle inhibition. A similar mechanistic effect was reported for the cyclic depsipeptide coibamide A, isolated from Leptolyngbya sp., and lyngbyabellin B, isolated from Lyngbya majuscule. The linear pentapeptides dolastatin 10 and symplostatin 1 were isolated from Symploca spp. and exhibited cytotoxic effects against human lung and breast cancer cell lines, via both Bcl-2 phosphorylation and caspase-3 protein activation. In addition, several different types of active peptides have been isolated from Lyngbya spp. and Nostoc spp., exhibiting anti-proliferative effects via microfilament disruption, secretory pathway inhibition and other intracellular mechanisms. Two novel cyclodepsipeptides, namely, scopularide A and B, isolated from the marine fungus Scopulariopsis brevicaulis, significantly inhibited the growth of pancreatic and colon cancer cell lines. Sansalvamide A is a structurally unique cyclic depsipeptide isolated from various marine fungi. This compound exhibited cytotoxic activities against different carcinomas, i.e., pancreatic, colon, breast and prostate sarcomas, as well as melanoma, representing a promising anticancer therapeutic lead. The exact mechanism of this depsipeptide is unknown, but a recent study showed an interaction between a heat shock protein (HSP90) and client cancer protein in a mammalian cell line. Sansalvamide A binds to the N-middle domain of HSP90 and allosterically inhibits protein complex formation, which is necessary for promotion of tumor growth.

7. Anticancer Bioactive Antibiotics Derived from Marine Sources

Toxins that originally evolved to kill competing microorganisms can have a variety of physiological effects and could function as novel targets for anticancer drug discovery. In many cases, the targets of these compounds are components of signal transduction cascades that are conserved in many species. Antitumor antibiotics are among the most important cancer chemotherapeutic agents and include members of the anthracycline, actinomycin, and aureolic acid families. Clinically useful agents from these families (Figure 3, Figure 8; Table 2) include peptolides, dactinomycin, was found to downregulate several glioma metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis, suggesting that targeting multiple tumor metabolic regulators might be a new anti-glioma mechanism of actinomycin D. Anthracyclines are among the most widely used antitumor antibiotics in the clinic and exert antitumor activity mainly by inhibiting topoisomerase II.

Geldanamycin is a natural fermentation product of the benzoquinone ansamycin and inhibits the heat shock protein HSP90, as well show cytotoxic effect against HeLa cells. Trabectedin and pegylated liposomal doxorubicin have been combined in a randomized phase III study to combat ovarian cancer in vivo and compared to pegylated liposomal doxorubicin alone. The three fused tetrahydroisoquinoline rings contributed to the trabectedin complex mechanism of action. It was claimed to block the substantial DNA and transcription interacting effect as the chemical structure binds to the minor groove of DNA covalently and interact with transcription factors (e.g., SP-1) directly. Another chemotherapeutic agent is bryostatin that modulates the paclitaxel inhibitor of protein kinase C (PKC).

Bryostatin 1, best known anticancer agent isolated from a species of bryozoan Bugula neritina, is able to induce ubiquitination and proteasome degradation of Bcl-2 in lymphoblastic leukemia and permits the growth of progenitor cells from bone marrow. Bryostatins are potent activators of protein kinase C (PKC) and regulate the activation, growth, and differentiation of cells. Some of the other suggested mechanism of actions were illustrated and included cell cycle arrest, inhibition of protein synthesis and antiangiogenic activity corresponding to didemnin B and aplidine. Several pathways are proposed for kahalalide F with specific interactions with cell membrane proteins. Aplidine displays promising anti-proliferative activity (currently in phase I–II trials) via characterized delay of neuromuscular toxicity and promising anti-proliferative activity (Figure 8). Squalamine, neovastat, and LAF389 were investigated for their antiangiogenic activity where squalamine and neovastat are currently tested in phase II and III studies, respectively. Squalamine and LAF389 inhibited sodium hydrogen antiporter sodium-proton exchangers thus targeting the phospholipid bilayer, and with LAF389 entered phase I trial. On the other hand, neovastat stops the binding of VEGF to its receptor. Plinabulin (NPI-2358), a potent and selective vascular disrupting agent (VDA) isolated from a marine fungal extract, is presently undergoing phase II clinical trials because of its activity against multi-drug resistant human tumor cell lines. Tasidotin, Synthadotin (ILX-651), derived from a marine bacterium in phase II clinical trials, and Soblidotin (TZT 1027), the bacterial peptide of marine origin in phase III clinical trials, are promising anticancer agents.

Salinosporamide A, a novel long-lasting proteasome inhibitor isolated from a marine bacterium Salinispora tropica in phase I clinical trials, has more efficacy against a wider range of hematologic malignancies and many solid tumor models, and less cytotoxicity to normal cells (Figure 8). Sorbicillactone-A, is an alkaloid produced by Penicillium chrysogenum and associated with marine sponge Ircinia fasciculate, showed antileukemic properties. Depsipeptide (NSC 630176), a bicyclic peptide isolated from Chromobacterium violaceum, decreased the mRNA expression of the c-MYC oncogene, causing cell-cycle arrest at G0-G1 and acting as an inhibitor of a histone deacetylase.

8. Chemical Property Space

The chemical global positioning system of natural products shortly called ChemGPS-NP was used to investigate the chemical property space produced by the marine compounds in this review. The chemical structures were converted to SMILES (simplified molecular-input line-entry system), formats using Chemsketsh, and submitted to ChemGPS-NPweb. Eight principle component (PC) values were obtained based on 35 molecular descriptors for each compound. The three major values were plotted on three dimensions graphs as PC1, PC2, and PC3 in order to indicate among others; the size, weight, aromaticity, rigidity, and lipophilicity. Principle component analysis represents the most group of variant properties where every position indicates a compound-specific value in a virtual chemical property space. Figure 9 showed the diversities of studied marine compounds within their respective chemical class as their specific positions did not form a tight cluster in chemical property space. The unique diversity within a single chemical class was noted to be in agreement with Muigg et al 2013 who reported a unique distinction between marine and terrestrial compounds by using chemical property space. For example, marine peptides did spread over and did not form a close cluster forms indicating an interesting diversity within a similar chemical class. The demonstration of marine anticancer compounds as a set of compounds in term of chemical property space can be used to compare different activities using other specific set or databases. Natural marine compounds are no exception from the natural compounds that continue to be a source of unique diversity even by their chemical-property.

9. Conclusions

Several marine natural products have been found to exhibit anticancer activity in vitro on a wide range of tumor cell lines, including renal, lung, prostate, bladder, melanoma, osteosarcoma, mammary, and lymphoid cancer-derived cell lines. In addition, most of the reports on the mechanism of action of marine products in inhibiting tumor growth both in vitro and in vivo suggest it is mediated via apoptosis, necrosis, and lysis of the tumor cells. Marine flora, including microalgae, fungi, seaweeds, mangroves, bacteria, cyanobacteria, actinobacteria, and halophytes were found to have anticancer activity in in vitro and in vivo models are extremely important oceanic resources. In this context, reports on the bioactive molecules combating a wide range of tumor cells such as prostate, bladder, renal, lung, mammary, melanoma, bone, and blood cancers, together with the known knowledge of the mechanism of action mediated via necrosis, apoptosis, and tumor cells lysis were discussed herein to illustrate the medicinally potent chemicals associated with the discovery of new anti-cancer drugs. Polyphenols, polysaccharides, alkaloids, peptides, and terpenoids (cembranoids) are some of the potential marine organism metabolites (Table 2), that exhibited an array of antioxidant, antitumor activities, in addition to immunostimulation. The technological innovation and scientific advances provided a baseline for exploring a great scope of the chemically unique, biologically active, and taxonomically diverse marine floras. Eribulin, trabectedin, cytarabine, and brentuximab vedotin, derived from marine resources, are some of the successful examples that predominantly have proven effective in preventing oxidative damage of DNA, induce apoptosis, control carcinogenesis and activate macrophages in pre-clinical and clinical trials. In this review, we summarized the contributions of marine natural products to treat cancer via modulation of cancer-related factors involving oxidative stress, inflammation, and cell survival. We discussed the pharmaceutical prospects and the chemical space properties that provided crucial insights and valuable knowledge on the largely unexplored marine flora-based anticancer leads. Although more detailed investigations are essential to meet the most common challenges of the clinical utility, it is clear that marine products are promising in providing a platform for improving the anti-cancer therapeutic strategies.

References 235

  1. 1.

    Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68:394-424.

    Not in our library10.3322/caac.21492

  2. 2.

    White M.C., Holman D.M., Boehm J.E., Peipins L.A., Grossman M., Henley S.J. Age and cancer risk: A potentially modifiable relationship. Am. J. Prev. Med. 2014;46:S7-S15.

    Not in our library10.1016/j.amepre.2013.10.029

  3. 3.

    Gurib-Fakim A. Medicinal plants: Traditions of yesterday and drugs of tomorrow. Mol. Asp. Med. 2006;27:93.

    Not in our library10.1016/j.mam.2005.07.008

  4. 4.
    A perspective on multi‐target drug discovery and design for complex diseases · 2018
    No notice
  5. 5.

    Garattini S., La Vecchia C. Perspectives in cancer chemotherapy. Eur. J. Cancer. 2001;37:128-147.

    Not in our library10.1016/s0959-8049(01)00265-9

  6. 6.

    Ang K.K.H., Holmes M.J., Higa T., Hamann M.T., Kara U.A.K. In vivo antimalarial activity of the beta-carboline alkaloid manzamine A. Antimicrob. Agents Chemother. 2000;44:1645-1649.

    Not in our library10.1128/aac.44.6.1645-1649.2000

  7. 7.

    Ang K., Holmes M., Kara U. Immune-mediated parasite clearance in mice infected with Plasmodium berghei following treatment with manzamine A. Parasitol. Res. 2001;87:715-721.

    Not in our library10.1007/s004360000366

  8. 8.

    Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359-E386.

    Not in our library10.1002/ijc.29210

  9. 9.

    World Health Organization. Global Status Report on Noncommunicable Diseases 2014. 2014.

    Not in our library

  10. 10.

    Sawadogo W., Boly R., Cerella C., Teiten M., Dicato M., Diederich M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2012. Molecules. 2015;20:7097-7142.

    Not in our library10.3390/molecules20047097

  11. 11.

    Butler M.S. The role of natural product chemistry in drug discovery. J. Nat. Prod. 2004;67:2141-2153.

    Not in our library10.1021/np040106y

  12. 12.

    Newman D.J., Cragg G.M., Snader K.M. Natural products as sources of new drugs over the period 1981–2002. J. Nat. Prod. 2003;66:1022-1037.

    Not in our library10.1021/np030096l

  13. 13.

    Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012;75:311-335.

    Not in our library10.1021/np200906s

  14. 14.

    Newman D.J., Cragg G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016;79:629-661.

    Not in our library10.1021/acs.jnatprod.5b01055

  15. 15.

    White J. Drug Addiction: From Basic Research to Therapy. Drug Alcohol Rev. 2009;28:455.

    Not in our library10.1111/j.1465-3362.2009.00088_1.x

  16. 16.

    Nobili S., Lippi D., Witort E., Donnini M., Bausi L., Mini E., Capaccioli S. Natural compounds for cancer treatment and prevention. Pharmacol. Res. 2009;59:365-378.

    Not in our library10.1016/j.phrs.2009.01.017

  17. 17.
    Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development · 2014
    No notice
  18. 18.

    Newman D.J., Gordon M.C. Drugs and drug candidates from marine sources: An assessment of the current “state of play”. Planta Med. 2016;82:775-789.

    Not in our library10.1055/s-0042-101353

  19. 19.

    Bhanot A., Sharma R., Noolvi M.N. Natural sources as potential anti-cancer agents: A review. Int. J. Phytomedicine. 2011;3:9-26.

    Not in our library

  20. 20.
    Marine Compounds and Cancer: 2017 Updates · 2018
    Not checked
  21. 21.

    Drug Bank.

    Not in our library

  22. 22.

    Walsh V., Goodman J. Cancer chemotherapy, biodiversity, public and private property: The case of the anti-cancer drug Taxol. Soc. Sci. Med. 1999;49:1215-1225.

    Not in our library10.1016/s0277-9536(99)00161-6

  23. 23.

    Mugera G.M. Useful Drugs and Cancer Causing Chemicals in Kenya Medical and Toxic Plants. 1977.

    Not in our library

  24. 24.

    Yousaf M., Hammond N.L., Peng J., Wahyuono S., McIntosh K.A., Charman W.N., Mayer A.M.S., Hamann M.T. New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. J. Med. Chem. 2004;47:3512-3517.

    Not in our library10.1021/jm030475b

  25. 25.

    Choudhary A., Naughton L., Montánchez I., Dobson A., Rai D. Current status and future prospects of marine natural products (MNPs) as antimicrobials. Mar. Drugs. 2017;15:272.

    Not in our library10.3390/md15090272

  26. 26.
    Computational Methodologies in the Exploration of Marine Natural Product Leads · 2018
    Not checked
  27. 27.

    Malakoff D. Extinction on the high seas. Science. 1997;227:486-488.

    Not in our library10.1126/science.277.5325.486

  28. 28.

    Boeuf G. Marine biodiversity characteristics. Comptes Rendus Biol. 2011;334:435-440.

    Not in our library10.1016/j.crvi.2011.02.009

  29. 29.

    Whitman W.B. The unseen majority. Proc. Natl. Acad. Sci. USA. 1998;74:5088-5090.

    Not in our library10.1073/pnas.95.12.6578

  30. 30.

    Rocha-Martin J., Harrington C., Dobson A., O’Gara F. Emerging strategies and integrated systems microbiology technologies for biodiscovery of marine bioactive compounds. Mar. Drugs. 2014;12:3516-3559.

    Not in our library10.3390/md12063516

  31. 31.
    Anticancer Drugs from Marine Flora: An Overview · 2010
    No notice
  32. 32.

    Ramirez-Llodra E., Brandt A., Danovaro R., De Mol B., Escobar E., German C., Levin L., Arbizu P., Menot L., Buhl-Mortensen P. Deep, diverse and definitely different: Unique attributes of the world’s largest ecosystem. Biogeosciences. 2010;7:2851-2899.

    Not in our library10.5194/bg-7-2851-2010

  33. 33.

    Bergmann W., Feeney R.J. The isolation of a new thymine pentoside from sponges1. J. Am. Chem. Soc. 1950;72:2809-2810.

    Not in our library10.1021/ja01162a543

  34. 34.

    Cragg G.M., Newman D.J., Weiss R.B. Coral reefs, forests, and thermal vents: The worldwide exploration of nature for novel antitumor agents. Semin. Oncol. 1997;24:156-163.

    Not in our library

  35. 35.

    Bergmann W., Feeney R.J. Nucleosides of sponges: Discovery of the arabinosebased nucleotides—Tethya crypta. J. Org. Chem. 1951;16:981-987.

    Not in our library10.1021/jo01146a023

  36. 36.

    Bergmann W., Feeney R.J. Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. 1 Spongothymidine and spongouridine2. J. Org. Chem. 1955;20:1501-1507.

    Not in our library10.1021/jo01128a007

  37. 37.

    Rinehart K.L. Antitumor compounds from tunicates. Med. Res. Rev. 2000;20:27.

    Not in our library10.1002/(sici)1098-1128(200001)20:1<1::aid-med1>3.0.co;2-a

  38. 38.

    Schwartsmann G., Brondani A., Berlinck R.G.S., Jimeno J. Marine organisms and other novel natural sources of new cancer drugs. Ann. Oncol. 2000;11:235-243.

    Not in our library10.1093/annonc/11.suppl_3.235

  39. 39.

    Fsulkner D.J. Highlights of marine natural products chemistry (1972–1999). Nat. Prod. Rep. 2000;17:1-6.

    Not in our library10.1093/annonc/11.suppl_3.235

  40. 40.

    Faulkner D.J. Marine pharmacology. Antonie Van Leeuwenhoek. 2000;77:135-145.

    Not in our library10.1023/a:1002405815493

  41. 41.

    Garcia-Fernandez L.F., Reyes F., Sanchez-Puelles J.M. The marine pharmacy: New antitumoral compounds from the sea. Pharm. News. 2002;9:495-502.

    Not in our library

  42. 42.

    Haefner B. Drugs from the deep: Marine natural products as drug candidates. Drug Discov. Today. 2003;8:536-544.

    Not in our library10.1016/s1359-6446(03)02713-2

  43. 43.

    Laatsch H. AntiBase 2011: The Natural Compound Identifier. 2011;Volume 313.

    Not in our library

  44. 44.

    Newman D.J., Cragg G.M. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr. Med. Chem. 2004;11:1693-1713.

    Not in our library10.2174/0929867043364982

  45. 45.

    Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007;70:461-477.

    Not in our library10.1021/np068054v

  46. 46.

    Kim W., Kim Y., Kim J., Nam B.-H., Kim D.-G., An C., Lee J., Kim P., Lee H., Oh J.-S. Liquid chromatography-mass spectrometry-based rapid secondary-metabolite profiling of marine Pseudoalteromonas sp. M2. Mar. Drugs. 2016;14:24.

    Not in our library10.3390/md14010024

  47. 47.

    Fries E., Dekiff J.H., Willmeyer J., Nuelle M.-T., Ebert M., Remy D. Identification of polymer types and additives in marine microplastic particles using pyrolysis-GC/MS and scanning electron microscopy. Environ. Sci. Process. Impacts. 2013;15:1949-1956.

    Not in our library10.1039/c3em00214d

  48. 48.

    Krock B., Busch J., Tillmann U., García-Camacho F., Sánchez-Mirón A., Gallardo-Rodríguez J., López-Rosales L., Andree K., Fernández-Tejedor M., Witt M. LC-MS/MS detection of karlotoxins reveals new variants in strains of the marine dinoflagellate Karlodinium veneficum from the Ebro Delta (NW Mediterranean). Mar. Drugs. 2017;15:391.

    Not in our library10.3390/md15120391

  49. 49.

    Bose U., Hewavitharana A., Ng Y., Shaw P., Fuerst J., Hodson M. LC-MS-Based metabolomics study of marine bacterial secondary metabolite and antibiotic production in Salinispora arenicola. Mar. Drugs. 2015;13:249-266.

    Not in our library10.3390/md13010249

  50. 50.

    Panagiotopoulos C., Repeta D.J., Mathieu L., Rontani J.-F., Sempere R. Molecular level characterization of methyl sugars in marine high molecular weight dissolved organic matter. Mar. Chem. 2013;154:34-45.

    Not in our library10.1016/j.marchem.2013.04.003

  51. 51.

    Freitas S., Martins R., Costa M., Leão P., Vitorino R., Vasconcelos V., Urbatzka R. Hierridin B isolated from a marine cyanobacterium alters VDAC1, mitochondrial activity, and cell cycle genes on HT-29 colon adenocarcinoma cells. Mar. Drugs. 2016;14:158.

    Not in our library10.3390/md14090158

  52. 52.

    Garson M., Hehre W., Pierens G. Revision of the structure of acremine P from a marine-derived strain of Acremonium persicinum. Molecules. 2017;22:521.

    Not in our library10.3390/molecules22040521

  53. 53.

    Macintyre L., Zhang T., Viegelmann C., Martinez I., Cheng C., Dowdells C., Abdelmohsen U., Gernert C., Hentschel U., Edrada-Ebel R. Metabolomic tools for secondary metabolite discovery from marine microbial symbionts. Mar. Drugs. 2014;12:3416-3448.

    Not in our library10.3390/md12063416

  54. 54.

    Pérez-Victoria I., Martín J., Reyes F. Combined LC/UV/MS and NMR strategies for the dereplication of marine natural products. Planta Med. 2016;82:857-871.

    Not in our library10.1055/s-0042-101763

  55. 55.

    Viegelmann C., Margassery L., Kennedy J., Zhang T., O’Brien C., O’Gara F., Morrissey J., Dobson A., Edrada-Ebel R. Metabolomic profiling and genomic study of a marine sponge-associated Streptomyces sp. Mar. Drugs. 2014;12:3323-3351.

    Not in our library10.3390/md12063323

  56. 56.

    Morvan D. Functional metabolomics uncovers metabolic alterations associated to severe oxidative stress in MCF7 breast cancer cells exposed to ascididemin. Mar. Drugs. 2013;11:3846-3860.

    Not in our library10.3390/md11103846

  57. 57.

    Huang C., Leung R.K.-K., Guo M., Tuo L., Guo L., Yew W.W., Lou I., Lee S.M.Y., Sun C. Genome-guided investigation of antibiotic substances produced by Allosalinactinospora lopnorensis CA15-2 T from Lop Nor region, China. Sci. Rep. 2016;6:20667.

    Not in our library10.1038/srep20667

  58. 58.

    Bourhill T., Narendran A., Johnston R.N. Enzastaurin: A lesson in drug development. Crit. Rev. Oncol. Hematol. 2017;112:72-79.

    Not in our library10.1016/j.critrevonc.2017.02.003

  59. 59.

    Wang Y.-Q., Miao Z.-H. Marine-derived angiogenesis inhibitors for cancer therapy. Mar. Drugs. 2013;11:903-933.

    Not in our library10.3390/md11030903

  60. 60.

    Ritchie J.W.A., Williams R.J. Cancer research UK centre for drug development: Translating 21st-century science into the cancer medicines of tomorrow. Drug Discov. Today. 2015;20:995-1003.

    Not in our library10.1016/j.drudis.2015.03.006

  61. 61.

    Ahmad I., Al-Katib A.M., Beck F.W.J., Mohammad R.M. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: Case report. Clin. Cancer Res. 2000;6:1328-1332.

    Not in our library

  62. 62.

    Garcia-carbonero R., Harmon D., Seiden M., Jimeno J., Merriam P., Waxman A., Supko J., Quigley M.T., Ryan D. Ecteinascidin-743 (et-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: Results from phase Ii trials. Ann. Oncol. 2000;11:126.

    Not in our library

  63. 63.

    Erba E., Bergamaschi D., Bassano L., Damia G., Ronzoni S., Faircloth G.T., d’Incalci M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer. 2001;37:97-105.

    Not in our library10.1016/s0959-8049(00)00357-9

  64. 64.

    Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr. Pharm. Des. 1999;5:139-162.

    Not in our library

  65. 65.

    Pathak S., Multani A.S., Ozen M., Richardson M.A., Newman R.A. Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. Oncol. Rep. 1998;5:373-379.

    Not in our library10.3892/or.5.2.373

  66. 66.

    Bai R., Petit G.R., Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 1990;39:1941-1949.

    Not in our library10.1016/0006-2952(90)90613-p

  67. 67.

    Dring M.J., Dring M.J., Dring M.H. The Biology of Marine Plants. 1991.

    Not in our library

  68. 68.

    Orlikova B., Legrand N., Panning J., Dicato M., Diederich M. Anti-inflammatory and anticancer drugs from nature. Advances in Nutrition and Cancer. 2014;123-143.

    Not in our library10.1007/978-3-642-38007-5_8

  69. 69.

    Bhosale S.H., Nagle V.L., Jagtap T.G. Antifouling potential of some marine organisms from India against species of Bacillus and Pseudomonas. Mar. Biotechnol. 2002;4:111-118.

    Not in our library10.1007/s10126-001-0087-1

  70. 70.

    Alghazwi M., Kan Y.Q., Zhang W., Gai W.P., Garson M.J., Smid S. Neuroprotective activities of natural products from marine macroalgae during 1999–2015. J. Appl. Phycol. 2016;28:3599-3616.

    Not in our library10.1007/s10811-016-0908-2

  71. 71.

    Ganesan P., Kumar C.S., Bhaskar N. Antioxidant properties of methanol extract and its solvent fractions obtained from selected Indian red seaweeds. Bioresour. Technol. 2008;99:2717-2723.

    Not in our library10.1016/j.biortech.2007.07.005

  72. 72.

    Carmichael W.W. Cyanobacteria secondary metabolites—the cyanotoxins. J. Appl. Bacteriol. 1992;72:445-459.

    Not in our library10.1111/j.1365-2672.1992.tb01858.x

  73. 73.

    Ibrahim E.A., Aly H.F., Baker D.A., Mahmoud K., El-Baz F.K. Marine algal sterol hydrocarbon with anti-inflammatory, anticancer and anti-oxidant properties. Int. J. Pharma Bio Sci. 2016;7:392-398.

    Not in our library

  74. 74.

    Bandaranayake W.M. Bioactivities, bioactive compounds and chemical constituents of mangrove plants. Wetl. Ecol. Manag. 2002;10:421-452.

    Not in our library10.1023/a:1021397624349

  75. 75.

    Mans D.R.A., Da Rocha A.B., Schwartsmann G. Anti-cancer drug discovery and development in Brazil: Targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist. 2000;5:185-198.

    Not in our library10.1634/theoncologist.5-3-185

  76. 76.

    Lavakumar V., Ahamed K.F.H., Ravichandran V. Anticancer and antioxidant effect of Acanthophora spicifera against EAC induced carcinoma in mice. J. Pharm. Res. 2012;5:1503-1507.

    Not in our library

  77. 77.

    Zhuang C., Itoh H., Mizuno T., Ito H. Antitumor active fucoidan from the brown seaweed, umitoranoo (Sargassum thunbergii). Biosci. Biotechnol. Biochem. 1995;59:563-567.

    Not in our library10.1271/bbb.59.563

  78. 78.

    Vischer P., Buddecke E. Different action of heparin and fucoidan on arterial smooth muscle cell proliferation and thrombospondin and fibronectin metabolism. Eur. J. Cell Biol. 1991;56:407-414.

    Not in our library

  79. 79.

    Barbier P., Guise S., Huitorel P., Amade P., Pesando D., Briand C., Peyrot V. Caulerpenyne from Caulerpa taxifolia has an antiproliferative activity on tumor cell line SK-N-SH and modifies the microtubule network. Life Sci. 2001;70:415-429.

    Not in our library10.1016/s0024-3205(01)01396-0

  80. 80.

    Palermo J.A., Flower P.B., Seldes A.M. Chondriamides A and B, new indolic metabolites from the red alga Chondria sp. Tetrahedron Lett. 1992;33:3097-3100.

    Not in our library10.1016/s0040-4039(00)79823-6

  81. 81.

    Parent-Massin D. Evaluation of the toxicological risk to humans of caulerpenyne using human hematopoietic progenitors, melanocytes, and keratinocytes in culture. J. Toxicol. Environ. Heal. Part A. 1996;47:47-59.

    Not in our library10.1080/009841096161924

  82. 82.

    Urones J.G., Araujo M.E.M., Palma F.M.S.B., Basabe P., Marcos I.S., Moro R.F., Lithgow A.M., Pineda J. Meroterpenes from Cystoseira usneoides II. Phytochemistry. 1992;31:2105-2109.

    Not in our library10.1016/0031-9422(92)80372-l

  83. 83.

    Fischel J.L., Lemee R., Formento P., Caldani C., Moll J.L., Pesando D., Meinesz A., Grelier P., Pietra P., Guerriero A. Cell growth inhibitory effects of caulerpenyne, a sesquiterpenoid from the marine algae Caulerpa taxifolia. Anticancer Res. 1995;15:2155-2160.

    Not in our library

  84. 84.

    Athukorala Y., Jung W.-K., Vasanthan T., Jeon Y.-J. An anticoagulative polysaccharide from an enzymatic hydrolysate of Ecklonia cava. Carbohydr. Polym. 2006;66:184-191.

    Not in our library10.1016/j.carbpol.2006.03.002

  85. 85.

    Gerwick W.H., Fenical W. Ichthyotoxic and cytotoxic metabolites of the tropical brown alga Stypopodium zonale (Lamouroux) Papenfuss. J. Org. Chem. 1981;46:22-27.

    Not in our library10.1021/jo00314a005

  86. 86.

    Encarnação T., Pais A.A., Campos M.G., Burrows H.D. Cyanobacteria and microalgae: A renewable source of bioactive compounds and other chemicals. Sci. Prog. 2015;98:145-168.

    Not in our library10.3184/003685015x14298590596266

  87. 87.

    Bachvaroff T.R., Adolf J.E., Squier A.H., Harvey H.R., Place A.R. Characterization and quantification of karlotoxins by liquid chromatography–mass spectrometry. Harmful Algae. 2008;7:473-484.

    Not in our library10.1016/j.hal.2007.10.003

  88. 88.

    Tan L.T. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry. 2007;68:954-979.

    Not in our library10.1016/j.phytochem.2007.01.012

  89. 89.

    Rickards R.W., Rothschild J.M., Willis A.C., de Chazal N.M., Kirk J., Kirk K., Saliba K.J., Smith G.D. Calothrixins A and B, novel pentacyclic metabolites from Calothrix cyanobacteria with potent activity against malaria parasites and human cancer cells. Tetrahedron. 1999;55:13513-13520.

    Not in our library10.1016/s0040-4020(99)00833-9

  90. 90.

    Schmidt E.W., Nelson J.T., Rasko D.A., Sudek S., Eisen J.A., Haygood M.G., Ravel J. Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, the cyanobacterial symbiont of Lissoclinum patella. Proc. Natl. Acad. Sci. USA. 2005;102:7315-7320.

    Not in our library10.1073/pnas.0501424102

  91. 91.

    Donia M.S., Hathaway B.J., Sudek S., Haygood M.G., Rosovitz M.J., Ravel J., Schmidt E.W. Natural combinatorial peptide libraries in cyanobacterial symbionts of marine ascidians. Nat. Chem. Biol. 2006;2:729.

    Not in our library10.1038/nchembio829

  92. 92.

    Donia M.S., Ravel J., Schmidt E.W. A global assembly line for cyanobactins. Nat. Chem. Biol. 2008;4:341.

    Not in our library10.1038/nchembio.84

  93. 93.

    Williams D.E., Moore R.E., Paul V.J. The structure of ulithiacyclamide B. Antitumor evaluation of cyclic peptides and macrolides from Lissoclinum patella. J. Nat. Prod. 1989;52:732-739.

    Not in our library10.1021/np50064a011

  94. 94.

    Banker R., Carmeli S. Tenuecyclamides A–D, Cyclic Hexapeptides from the Cyanobacterium Nostoc s pongiaeforme var. t enue. J. Nat. Prod. 1998;61:1248-1251.

    Not in our library10.1021/np980138j

  95. 95.

    Davidson B.S. New dimensions in natural products research: Cultured marine microorganisms. Curr. Opin. Biotechnol. 1995;6:284-291.

    Not in our library10.1016/0958-1669(95)80049-2

  96. 96.

    Moore R.E. Cyclic peptides and depsipeptides from cyanobacteria: A review. J. Ind. Microbiol. 1996;16:134-143.

    Not in our library10.1007/bf01570074

  97. 97.

    Trimurtulu G., Ohtani I., Patterson G.M.L., Moore R.E., Corbett T.H., Valeriote F.A., Demchik L. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV 224. J. Am. Chem. Soc. 1994;116:4729-4737.

    Not in our library10.1021/ja00090a020

  98. 98.

    Taori K., Paul V.J., Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J. Am. Chem. Soc. 2008;130:1806-1807.

    Not in our library10.1021/ja7110064

  99. 99.

    Luesch H., Moore R.E., Paul V.J., Mooberry S.L., Corbett T.H. Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J. Nat. Prod. 2001;64:907-910.

    Not in our library10.1021/np010049y

  100. 100.

    Medina R.A., Goeger D.E., Hills P., Mooberry S.L., Huang N., Romero L.I., Ortega-Barría E., Gerwick W.H., McPhail K.L. Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. J. Am. Chem. Soc. 2008;130:6324-6325.

    Not in our library10.1021/ja801383f

  101. 101.
    Immense Essence of Excellence: Marine Microbial Bioactive Compounds · 2010
    No notice
  102. 102.

    Stevenson C.S., Capper E.A., Roshak A.K., Marquez B., Grace K., Gerwick W.H., Jacobs R.S., Marshall L.A. Scytonemin-a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases. Inflamm. Res. 2002;51:112-114.

    Not in our library10.1007/bf02684014

  103. 103.

    Stevenson C.S., Capper E.A., Roshak A.K., Marquez B., Eichman C., Jackson J.R., Mattern M., Gerwick W.H., Jacobs R.S., Marshall L.A. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J. Pharmacol. Exp. Ther. 2002;303:858-866.

    Not in our library10.1124/jpet.102.036350

  104. 104.

    Carte B.K. Biomedical potential of marine natural products. Bioscience. 1996;46:271-286.

    Not in our library

  105. 105.

    Gerwick W.H., Proteau P.J., Nagle D.G., Hamel E., Blokhin A., Slate D.L. Structure of curacin A, a novel antimitotic, antiproliferative and brine shrimp toxic natural product from the marine cyanobacterium Lyngbya majuscula. J. Org. Chem. 1994;59:1243-1245.

    Not in our library10.1021/jo00085a006

  106. 106.

    Javed F., Qadir M.I., Janbaz K.H., Ali M. Novel drugs from marine microorganisms. Crit. Rev. Microbiol. 2011;37:245-249.

    Not in our library10.3109/1040841x.2011.576234

  107. 107.

    Peng J., Place A.R., Yoshida W., Anklin C., Hamann M.T. Structure and absolute configuration of karlotoxin-2, an ichthyotoxin from the marine dinoflagellate Karlodinium veneficum. J. Am. Chem. Soc. 2010;132:3277-3279.

    Not in our library10.1021/ja9091853

  108. 108.

    Romanenko L.A., Uchino M., Kalinovskaya N.I., Mikhailov V. V Isolation, phylogenetic analysis and screening of marine mollusc-associated bacteria for antimicrobial, hemolytic and surface activities. Microbiol. Res. 2008;163:633-644.

    Not in our library10.1016/j.micres.2006.10.001

  109. 109.

    Isnansetyo A., Kamei Y. Bioactive substances produced by marine isolates of Pseudomonas. J. Ind. Microbiol. Biotechnol. 2009;36:1239-1248.

    Not in our library10.1007/s10295-009-0611-2

  110. 110.

    Malaker A., Ahmad S.A.I. Therapeutic potency of anticancer peptides derived from marine organism. Int. J. Eng. 2013;2:2305-8269.

    Not in our library

  111. 111.

    Goldin B., Gorbach S.L. Alterations in fecal microflora enzymes related to diet, age, lactobacillus supplements, and dimethylhydrazine. Cancer. 1977;40:2421-2426.

    Not in our library10.1002/1097-0142(197711)40:5+<2421::aid-cncr2820400905>3.0.co;2-i

  112. 112.

    Mitall B.K., Garg S.K. Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Crit. Rev. Microbiol. 1995;21:175-214.

    Not in our library10.3109/10408419509113540

  113. 113.

    Wollowski I., Rechkemmer G., Pool-Zobel B.L. Protective role of probiotics and prebiotics in colon cancer. Am. J. Clin. Nutr. 2001;73:451s-455s.

    Not in our library10.1093/ajcn/73.2.451s

  114. 114.

    Bitzer J., Große T., Wang L., Lang S., Beil W., Zeeck A. New aminophenoxazinones from a marine Halomonas sp.: Fermentation, structure elucidation, and biological activity. J. Antibiot. (Tokyo). 2006;59:86.

    Not in our library10.1038/ja.2006.12

  115. 115.

    Sagar S., Esau L., Holtermann K., Hikmawan T., Zhang G., Stingl U., Bajic V.B., Kaur M. Induction of apoptosis in cancer cell lines by the Red Sea brine pool bacterial extracts. BMC Complement. Altern. Med. 2013;13:344.

    Not in our library10.1186/1472-6882-13-344

  116. 116.

    Ruiz-Ruiz C., Srivastava G.K., Carranza D., Mata J.A., Llamas I., Santamaría M., Quesada E., Molina I.J. An exopolysaccharide produced by the novel halophilic bacterium Halomonas stenophila strain B100 selectively induces apoptosis in human T leukaemia cells. Appl. Microbiol. Biotechnol. 2011;89:345-355.

    Not in our library10.1007/s00253-010-2886-7

  117. 117.

    Erba E., Bergamaschi D., Ronzoni S., Faretta M., Taverna S., Bonfanti M., Catapano C. V, Faircloth G., Jimeno J., D’incalci M. Mode of action of thiocoraline, a natural marine compound with anti-tumor activity. Br. J. Cancer. 1999;80:971.

    Not in our library10.1038/sj.bjc.6690451

  118. 118.

    Wang L., Groβe T., Stevens H., Brinkhoff T., Simon M., Liang L., Bitzer J., Bach G., Zeeck A., Tokuda H. Bioactive hydroxyphenylpyrrole-dicarboxylic acids from a new marine Halomonas sp.: Production and structure elucidation. Appl. Microbiol. Biotechnol. 2006;72:816-822.

    Not in our library10.1007/s00253-006-0370-1

  119. 119.

    Heald S.C., Brandão P.F.B., Hardicre R., Bull A.T. Physiology, biochemistry and taxonomy of deep-sea nitrile metabolising Rhodococcus strains. Antonie Van Leeuwenhoek. 2001;80:169-183.

    Not in our library10.1023/a:1012227302373

  120. 120.

    Moran M.A., Rutherford L.T., Hodson R.E. Evidence for indigenous Streptomyces populations in a marine environment determined with a 16S rRNA probe. Appl. Environ. Microbiol. 1995;61:3695-3700.

    Not in our library10.1128/aem.61.10.3695-3700.1995

  121. 121.

    Jensen P.R., Mincer T.J., Williams P.G., Fenical W. Marine actinomycete diversity and natural product discovery. Antonie Van Leeuwenhoek. 2005;87:43-48.

    Not in our library10.1007/s10482-004-6540-1

  122. 122.

    Maldonado L.A., Fenical W., Jensen P.R., Kauffman C.A., Mincer T.J., Ward A.C., Bull A.T., Goodfellow M. Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae. Int. J. Syst. Evol. Microbiol. 2005;55:1759-1766.

    Not in our library10.1099/ijs.0.63625-0

  123. 123.

    Mincer T.J., Fenical W., Jensen P.R. Culture-dependent and culture-independent diversity within the obligate marine actinomycete genus Salinispora. Appl. Environ. Microbiol. 2005;71:7019-7028.

    Not in our library10.1128/aem.71.11.7019-7028.2005

  124. 124.

    Genilloud O. Actinomycetes: Still a source of novel antibiotics. Nat. Prod. Rep. 2017;34:1203-1232.

    Not in our library10.1039/c7np00026j

  125. 125.
    Antitumor Compounds from Marine Actinomycetes · 2009
    No notice
  126. 126.

    Berdy J. Bioactive microbial metabolites. J. Antibiot. (Tokyo). 2005;58:1.

    Not in our library10.1038/ja.2005.1

  127. 127.
    Actinomycetes for Marine Drug Discovery Isolated from Mangrove Soils and Plants in China · 2009
    Corrected
  128. 128.

    Lam K.S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. Microbiol. 2006;9:245-251.

    Not in our library10.1016/j.mib.2006.03.004

  129. 129.

    Cho J.Y., Williams P.G., Kwon H.C., Jensen P.R., Fenical W. Lucentamycins A–D, cytotoxic peptides from the marine-derived actinomycete Nocardiopsis lucentensis. J. Nat. Prod. 2007;70:1321-1328.

    Not in our library10.1021/np070101b

  130. 130.

    Maskey R.P., Helmke E., Kayser O., Fiebig H.H., Maier A., Busche A., Laatsch H. Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine streptomycete and their absolute stereochemistry. J. Antibiot. (Tokyo). 2004;57:771-779.

    Not in our library10.7164/antibiotics.57.771

  131. 131.

    Hawas U.W., Shaaban M., Shaaban K.A., Speitling M., Maier A., Kelter G., Fiebig H.H., Meiners M., Helmke E., Laatsch H. Mansouramycins A–D, cytotoxic isoquinolinequinones from a marine Streptomycete. J. Nat. Prod. 2009;72:2120-2124.

    Not in our library10.1021/np900160g

  132. 132.

    Pérez M., Crespo C., Schleissner C., Rodríguez P., Zúñiga P., Reyes F. Tartrolon D, a cytotoxic macrodiolide from the marine-derived actinomycete Streptomyces sp. MDG-04-17-069. J. Nat. Prod. 2009;72:2192-2194.

    Not in our library10.1021/np9006603

  133. 133.

    Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8:407-419.

    Not in our library10.1016/j.ccr.2005.10.013

  134. 134.

    Fenical W., Jensen P.R., Palladino M.A., Lam K.S., Lloyd G.K., Potts B.C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009;17:2175-2180.

    Not in our library10.1016/j.bmc.2008.10.075

  135. 135.

    Newman D.J., Hill R.T. New drugs from marine microbes: The tide is turning. J. Ind. Microbiol. Biotechnol. 2006;33:539-544.

    Not in our library10.1007/s10295-006-0115-2

  136. 136.

    Bhadury P., Mohammad B.T., Wright P.C. The current status of natural products from marine fungi and their potential as anti-infective agents. J. Ind. Microbiol. Biotechnol. 2006;33:325.

    Not in our library10.1007/s10295-005-0070-3

  137. 137.

    Guerriero A., D’Ambrosio M., Cuomo V., Pietra F. A novel, degraded polyketidic lactone, leptosphaerolide, and its likely diketone precursor, leptosphaerodione. Isolation from cultures of the marine ascomycete Leptosphaeria oraemaris (Linder). Helv. Chim. Acta. 1991;74:1445-1450.

    Not in our library10.1002/hlca.19910740707

  138. 138.

    Pallenberg A.J., White J.D. The synthesis and absolute configuration of (+)-leptosphaerin. Tetrahedron Lett. 1986;27:5591-5594.

    Not in our library10.1016/s0040-4039(00)85273-9

  139. 139.

    Schiehser G.A., White J.D., Matsumoto G., Pezzanite J.O., Clardy J. The structure of leptosphaerin. Tetrahedron Lett. 1986;27:5587-5590.

    Not in our library10.1016/s0040-4039(00)85272-7

  140. 140.

    Abdel-Lateff A., König G.M., Fisch K.M., Höller U., Jones P.G., Wright A.D. New antioxidant hydroquinone derivatives from the algicolous marine fungus Acremonium sp. J. Nat. Prod. 2002;65:1605-1611.

    Not in our library10.1021/np020128p

  141. 141.

    Abdel-Lateff A., Klemke C., König G.M., Wright A.D. Two new xanthone derivatives from the algicolous marine fungus Wardomyces anomalus. J. Nat. Prod. 2003;66:706-708.

    Not in our library10.1021/np020518b

  142. 142.

    Suja M., Vasuki S., Sajitha N. Anticancer activity of compounds isolated from marine endophytic fungus Aspergillus terreus. World J. Pharm. Pharm. Sci. 2014;3:661-672.

    Not in our library

  143. 143.

    Tan D.S.P., Marchio C., Reis-Filho J.S. Hereditary breast cancer: From molecular pathology to tailored therapies. J. Clin. Pathol. 2008;61:1073-1082.

    Not in our library10.1136/jcp.2008.057950

  144. 144.

    Du L., Zhu T., Fang Y., Liu H., Gu Q., Zhu W. Aspergiolide A, a novel anthraquinone derivative with naphtho [1, 2, 3-de] chromene-2, 7-dione skeleton isolated from a marine-derived fungus Aspergillus glaucus. Tetrahedron. 2007;63:1085-1088.

    Not in our library10.1016/j.tet.2006.11.074

  145. 145.

    Du L., Feng T., Zhao B., Li D., Cai S., Zhu T., Wang F., Xiao X., Gu Q. Alkaloids from a deep ocean sediment-derived fungus Penicillium sp. and their antitumor activities. J. Antibiot. (Tokyo). 2010;63:165.

    Not in our library10.1038/ja.2010.11

  146. 146.
    Anthracenedione Derivatives as Anticancer Agents Isolated from Secondary Metabolites of the Mangrove Endophytic Fungi · 2010
    Not checked
  147. 147.

    Han B.-N., Hong L.-L., Gu B.-B., Sun Y.-T., Wang J., Liu J.-T., Lin H.-W. Natural Products from Sponges. Symbiotic Microbiomes of Coral Reefs Sponges and Corals. 2019;329-463.

    Not in our library

  148. 148.

    Newman D.J., Cragg G.M., Snader K.M. The influence of natural products upon drug discovery. Nat. Prod. Rep. 2000;17:215-234.

    Not in our library10.1039/a902202c

  149. 149.

    Hirata Y., Uemura D. Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl. Chem. 1986;58:701-710.

    Not in our library10.1351/pac198658050701

  150. 150.

    Zovko A., Novak M., Hååg P., Kovalerchick D., Holmlund T., Färnegårdh K., Ilan M., Carmeli S., Lewensohn R., Viktorsson K. Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells. Oncotarget. 2016;7:50258.

    Not in our library10.18632/oncotarget.10361

  151. 151.

    Cortes J., O’Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., Chollet P., Manikas A., Diéras V., Delozier T. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet. 2011;377:914-923.

    Not in our library10.1016/s0140-6736(11)60070-6

  152. 152.

    Ei-Seedi H.R., Gomaa M., Salem M.M., Benchoula K., Keshk H.M., Yosri N., Ayesh A., Asker A.M., Soliman K., Hamza Z. Cytotoxic effects of the Red Sea soft coral Sarcophyton Trocheliophorum. Acta Pol. Pharm. 2016;73:1587-1592.

    Not in our library

  153. 153.

    Gomaa M.N., Soliman K., Ayesh A., Abd El-Wahed A., Hamza Z., Mansour H.M., Khalifa S.A.M., Mohd Ali H.B., El-Seedi H.R. Antibacterial effect of the red sea soft coral Sarcophyton trocheliophorum. Nat. Prod. Res. 2016;30:729-734.

    Not in our library10.1080/14786419.2015.1040991

  154. 154.

    Gross H., Kehraus S., Nett M., König G.M., Beil W., Wright A.D. New cytotoxic cembrane based diterpenes from the soft corals Sarcophyton cherbonnieri and Nephthea sp. Org. Biomol. Chem. 2003;1:944-949.

    Not in our library10.1039/b210039h

  155. 155.

    Chao C.-H., Wen Z.-H., Wu Y.-C., Yeh H.-C., Sheu J.-H. Cytotoxic and anti-inflammatory cembranoids from the soft coral Lobophytum crassum. J. Nat. Prod. 2008;71:1819-1824.

    Not in our library10.1021/np8004584

  156. 156.

    Spada P.D.S., de Souza G.G.N., Bortolini G.V., Henriques J.A.P., Salvador M. Antioxidant, mutagenic, and antimutagenic activity of frozen fruits. J. Med. Food. 2008;11:144-151.

    Not in our library10.1089/jmf.2007.598

  157. 157.

    Mohsen S.M., Ammar A.S.M. Total phenolic contents and antioxidant activity of corn tassel extracts. Food Chem. 2009;112:595-598.

    Not in our library10.1016/j.foodchem.2008.06.014

  158. 158.

    Shan X.U., Li L., Li-Qun Z., Zhuo L., Li-Li Q., Qi C., Chang-Fen X. Reversal effect of 4’-methylether-scutellarein on multidrug resistance of human choriocarcinoma JAR/VP16 cell line. Prog. Biochem. Biophys. 2006;33:1061-1073.

    Not in our library

  159. 159.

    Gawron A., Kruk I. Cytotoxic effect of xanthotoxol (8-hydroxypsoralen) on TCTC cells in vitro. Pol. J. Pharmacol. Pharm. 1992;44:51-57.

    Not in our library

  160. 160.

    Fan G.J., Han B.H., Kang Y.H., Park M.K. Evaluation of inhibitory potentials of chinese medicinal plants on platelet-activating factor (PAF) receptor binding. Nat. Prod. Sci. 2001;7:33-37.

    Not in our library

  161. 161.

    Shahidi F., Janitha P.K., Wanasundara P.D. Phenolic antioxidants. Crit. Rev. Food Sci. Nutr. 1992;32:67-103.

    Not in our library10.1080/10408399209527581

  162. 162.

    Sánchez-Moreno C., Larrauri J.A., Saura-Calixto F. Free radical scavenging capacity and inhibition of lipid oxidation of wines, grape juices and related polyphenolic constituents. Food Res. Int. 1999;32:407-412.

    Not in our library10.1016/s0963-9969(99)00097-6

  163. 163.

    Yuan Y. V, Carrington M.F., Walsh N.A. Extracts from dulse (Palmaria palmata) are effective antioxidants and inhibitors of cell proliferation in vitro. Food Chem. Toxicol. 2005;43:1073-1081.

    Not in our library10.1016/j.fct.2005.02.012

  164. 164.

    Zhao M., Yang B., Wang J., Liu Y., Yu L., Jiang Y. Immunomodulatory and anticancer activities of flavonoids extracted from litchi (Litchi chinensis Sonn.) pericarp. Int. Immunopharmacol. 2007;7:162-166.

    Not in our library10.1016/j.intimp.2006.09.003

  165. 165.

    Gorelik E. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Cancer Res. 1987;47:809-815.

    Not in our library

  166. 166.

    Yim J.H., Son E., Pyo S., Lee H.K. Novel sulfated polysaccharide derived from red-tide microalga Gyrodinium impudicum strain KG03 with immunostimulating activity in vivo. Mar. Biotechnol. 2005;7:331-338.

    Not in our library10.1007/s10126-004-0404-6

  167. 167.

    Zhou G., Xin H., Sheng W., Sun Y., Li Z., Xu Z. In vivo growth-inhibition of S180 tumor by mixture of 5-Fu and low molecular λ-carrageenan from Chondrus ocellatus. Pharmacol. Res. 2005;51:153-157.

    Not in our library10.1016/j.phrs.2004.07.003

  168. 168.

    Gorelik E., Bere W.W., Herberman R.B. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int. J. Cancer. 1984;33:87-94.

    Not in our library10.1002/ijc.2910330115

  169. 169.

    Dziarski R. Synergistic enhancement of T cell responses and interleukin-1 receptor expression by interleukin-1 and heparin or dextran sulfate. Cell. Immunol. 1992;145:100-110.

    Not in our library10.1016/0008-8749(92)90316-h

  170. 170.

    Dziarski R. Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J. Immunol. 1989;143:356-365.

    Not in our library

  171. 171.

    O’Sullivan G.M., Boswell C.M., Halliday G.M. Langerhans cell migration is modulated by N-sulfated glucosamine moieties in heparin. Exp. Dermatol. 2000;9:25-33.

    Not in our library10.1034/j.1600-0625.2000.009001025.x

  172. 172.

    Matsuda M., Yamori T., Naitoh M., Okutani K. Structural revision of sulfated polysaccharide B-1 isolated from a marine Pseudomonas species and its cytotoxic activity against human cancer cell lines. Mar. Biotechnol. 2003;5:13-19.

    Not in our library10.1007/s10126-002-0046-5

  173. 173.

    Joyce J.A., Freeman C., Meyer-Morse N., Parish C.R., Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 2005;24:4037.

    Not in our library10.1038/sj.onc.1208602

  174. 174.

    Berry D., Lynn D.M., Sasisekharan R., Langer R. Poly (β-amino ester) s promote cellular uptake of heparin and cancer cell death. Chem. Biol. 2004;11:487-498.

    Not in our library10.1016/j.chembiol.2004.03.023

  175. 175.

    Itoh H., Noda H., Amano H., Ito H. Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassum thunbergii. Anticancer Res. 1995;15:1937-1947.

    Not in our library

  176. 176.

    Berteau O., Mulloy B. Sulfated fucans, fresh perspectives: Structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology. 2003;13:29R-40R.

    Not in our library10.1093/glycob/cwg058

  177. 177.

    Itoh H., Noda H., Amano H., Zhuaug C., Mizuno T., Ito H. Antitumor activity and immunological properties of marine algal polysaccharides, especially fucoidan, prepared from Sargassum thunbergii of Phaeophyceae. Anticancer Res. 1993;13:2045-2052.

    Not in our library

  178. 178.

    Boisson-Vidal C., Zemani F., Caligiuri G., Galy-Fauroux I., Colliec-Jouault S., Helley D., Fischer A.-M. Neoangiogenesis induced by progenitor endothelial cells: Effect of fucoidan from marine algae. Cardiovasc. Hematol. Agents Med. Chem. (Former. Curr. Med. Chem. Hematol. Agents). 2007;5:67-77.

    Not in our library10.2174/187152507779315778

  179. 179.

    Aisa Y., Miyakawa Y., Nakazato T., Shibata H., Saito K., Ikeda Y., Kizaki M. Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways. Am. J. Hematol. 2005;78:7-14.

    Not in our library10.1002/ajh.20182

  180. 180.

    Gross H., Goeger D.E., Hills P., Mooberry S.L., Ballantine D.L., Murray T.F., Valeriote F.A., Gerwick W.H. Lophocladines, bioactive alkaloids from the red alga Lophocladia sp. J. Nat. Prod. 2006;69:640-644.

    Not in our library10.1021/np050519e

  181. 181.

    Ma D., Zou B., Cai G., Hu X., Liu J.O. Total synthesis of the cyclodepsipeptide apratoxin A and its analogues and assessment of their biological activities. Chem. Eur. J. 2006;12:7615-7626.

    Not in our library10.1002/chem.200600599

  182. 182.

    Marquez B.L., Watts K.S., Yokochi A., Roberts M.A., Verdier-Pinard P., Jimenez J.I., Hamel E., Scheuer P.J., Gerwick W.H. Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. J. Nat. Prod. 2002;65:866-871.

    Not in our library10.1021/np0106283

  183. 183.

    Mooberry S.L., Leal R.M., Tinley T.L., Luesch H., Moore R.E., Corbett T.H. The molecular pharmacology of symplostatin 1: A new antimitotic dolastatin 10 analog. Int. J. Cancer. 2003;104:512-521.

    Not in our library10.1002/ijc.10982

  184. 184.

    Kalemkerian G.P., Ou X., Adil M.R., Rosati R., Khoulani M.M., Madan S.K., Pettit G.R. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification. Cancer Chemother. Pharmacol. 1999;43:507-515.

    Not in our library10.1007/s002800050931

  185. 185.

    Costa M., Costa-Rodrigues J., Fernandes M.H., Barros P., Vasconcelos V., Martins R. Marine cyanobacteria compounds with anticancer properties: A review on the implication of apoptosis. Mar. Drugs. 2012;10:2181-2207.

    Not in our library10.3390/md10102181

  186. 186.

    Yu Z., Lang G., Kajahn I., Schmaljohann R., Imhoff J.F. Scopularides A and B, cyclodepsipeptides from a marine sponge-derived fungus, Scopulariopsis brevicaulis. J. Nat. Prod. 2008;71:1052-1054.

    Not in our library10.1021/np070580e

  187. 187.

    Vasko R.C., Rodriguez R.A., Cunningham C.N., Ardi V.C., Agard D.A., McAlpine S.R. Mechanistic studies of Sansalvamide A-amide: An allosteric modulator of Hsp90. ACS Med. Chem. Lett. 2010;1:4-8.

    Not in our library10.1021/ml900003t

  188. 188.

    Sabina H., Aliya R. Seaweed as a new source of flavone, scutellarein 4′-methyl-ether. Pak. J. Bot. 2009;41:1927-1930.

    Not in our library

  189. 189.

    Devi S.K., Velmurugan D. Molecular modeling, quantitative structure activity relationship and pharmacophore studies on antiǧviral, antiǧmalarial and antiǧinflammatory bioactive compounds from marine sources. Asian J. Pharm. Clin. Res. 2015;8:36-43.

    Not in our library

  190. 190.

    Lopes-Costa E., Abreu M., Gargiulo D., Rocha E., Ramos A.A. Anticancer effects of seaweed compounds fucoxanthin and phloroglucinol, alone and in combination with 5-fluorouracil in colon cells. J. Toxicol. Environ. Heal. Part A. 2017;80:776-787.

    Not in our library10.1080/15287394.2017.1357297

  191. 191.

    Magalhaes K.D., Costa L.S., Fidelis G.P., Oliveira R.M., Nobre L.T.D.B., Dantas-Santos N., Camara R.B.G., Albuquerque I.R.L., Cordeiro S.L., Sabry D.A. Anticoagulant, antioxidant and antitumor activities of heterofucans from the seaweed Dictyopteris delicatula. Int. J. Mol. Sci. 2011;12:3352-3365.

    Not in our library10.3390/ijms12053352

  192. 192.

    Kale V., Freysdottir J., Paulsen B.S., Friðjónsson Ó.H., Hreggviðsson G.O., Omarsdottir S. Sulphated polysaccharide from the sea cucumber Cucumaria frondosa affect maturation of human dendritic cells and their activation of allogeneic CD4 (+) T cells in vitro. Bioact. Carbohydr. Diet. Fibre. 2013;2:108-117.

    Not in our library10.1016/j.bcdf.2013.09.009

  193. 193.

    Clinical Trial.gov.

    Not in our library

  194. 194.

    Drug Bank.

    Not in our library

  195. 195.
    New Metabolites and Bioactive Actinomycins from Marine-Derived Streptomyces sp. ZZ338 · 2016
    Not checked
  196. 196.

    Clinical Trial.gov.

    Not in our library

  197. 197.

    Drug Bank.

    Not in our library

  198. 198.

    Da Rocha A.B., Lopes R.M., Schwartsmann G. Natural products in anticancer therapy. Curr. Opin. Pharmacol. 2001;1:364-369.

    Not in our library10.1016/s1471-4892(01)00063-7

  199. 199.

    Drug Bank.

    Not in our library

  200. 200.

    Clinical Trial.gov.

    Not in our library

  201. 201.

    Clinical Trial.gov.

    Not in our library

  202. 202.

    Drug Bank.

    Not in our library

  203. 203.

    Clinical Trial.gov.

    Not in our library

  204. 204.

    Drug Bank.

    Not in our library

  205. 205.

    Clinical Trials.gov.

    Not in our library

  206. 206.

    Drug Bank.

    Not in our library

  207. 207.

    Clinical Trials.gov.

    Not in our library

  208. 208.

    Drug Bank.

    Not in our library

  209. 209.

    Clinical Trials.gov.

    Not in our library

  210. 210.

    Drug Bank.

    Not in our library

  211. 211.

    Clinical Trial.gov.

    Not in our library

  212. 212.

    Clinical Trial.gov.

    Not in our library

  213. 213.

    Adjei A.A. Signal transduction pathway targets for anticancer drug discovery. Curr. Pharm. Des. 2000;6:361-378.

    Not in our library10.2174/1381612003400821

  214. 214.

    Lu J., Ma Y., Liang J., Xing Y., Xi T., Lu Y. Aureolic acids from a marine-derived Streptomyces sp. WBF16. Microbiol. Res. 2012;167:590-595.

    Not in our library10.1016/j.micres.2012.06.001

  215. 215.

    Tewey K.M., Chen G.L., Nelson E.M., Liu L.-F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 1984;259:9182-9187.

    Not in our library

  216. 216.

    Shi J.-G., Jia Z.-J., Cui Y.-X. Novel tricyclic diterpenoids from Euphorbia micractina. J. Nat. Prod. 1995;58:51-56.

    Not in our library10.1021/np50115a006

  217. 217.

    Wu D., Sorg B., Hecker E. New myrsinol-related polyfunctional pentacyclic diterpene esters from roots of Euphorbia prolifera. J. Nat. Prod. 1995;58:408-413.

    Not in our library10.1021/np50117a009

  218. 218.

    Albers M.W., Williams R.T., Brown E.J., Tanaka A., Hall F.L., Schreiber S.L. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J. Biol. Chem. 1993;268:22825-22829.

    Not in our library

  219. 219.

    Zunino F., Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anti-cancer. Drug Des. 1990;5:307-317.

    Not in our library

  220. 220.

    Cardenas M.E., Sanfridson A., Cutler N.S., Heitman J. Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 1998;16:427-433.

    Not in our library10.1016/s0167-7799(98)01239-6

  221. 221.

    Lin H.-N., Wang K.-L., Wu Z.-H., Tian R.-M., Liu G.-Z., Xu Y. Biological and chemical diversity of bacteria associated with a marine flatworm. Mar. Drugs. 2017;15:281.

    Not in our library10.3390/md15090281

  222. 222.

    Monk B.J., Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F.M., Pujade-Lauraine E., Lisyanskaya A.S., Makhson A.N., Rolski J. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 2010;28:3107-3114.

    Not in our library10.1200/jco.2009.25.4037

  223. 223.

    Carter N.J., Keam S.J. Trabectedin. Drugs. 2007;67:2257-2276.

    Not in our library10.2165/00003495-200767150-00009

  224. 224.

    Kortmansky J., Schwartz G.K. Bryostatin-1: A novel PKC inhibitor in clinical development. Cancer Investig. 2003;21:924-936.

    Not in our library10.1081/cnv-120025095

  225. 225.

    Sekar M., Poomalai S., Gunasekaran M., Mani P., Krishnamurthy A. Bioactive compounds from marine yeast inhibits lung cancer. J. Appl. Pharm. Sci. 2015;5:7-15.

    Not in our library

  226. 226.

    Wall N.R., Mohammad R.M., Reddy K.B., Al-Katib A.M. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh. Int. J. Mol. Med. 2000;5:165-236.

    Not in our library10.3892/ijmm.5.2.165

  227. 227.

    Singh R., Sharma M., Joshi P., Rawat D.S. Clinical status of anti-cancer agents derived from marine sources. Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem. Agents). 2008;8:603-617.

    Not in our library10.2174/187152008785133074

  228. 228.

    Dumez H., Gall H., Capdeville R., Dutreix C., van Oosterom A.T., Giaccone G. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anti-Cancer Drugs. 2007;18:219-225.

    Not in our library10.1097/cad.0b013e328010ef5b

  229. 229.

    Simmons T.L., Andrianasolo E., McPhail K., Flatt P., Gerwick W.H. Marine natural products as anticancer drugs. Mol. Cancer Ther. 2005;4:333-342.

    Not in our library

  230. 230.

    Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. 2003;42:355-357.

    Not in our library10.1002/anie.200390115

  231. 231.

    Thakur N.L., Thakur A.N. Marine Biotechnology: An overview. Indian J. Biotechnol. 2006;5:263-268.

    Not in our library

  232. 232.

    Schwartsmann G., da Rocha A.B., Berlinck R.G.S., Jimeno J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001;2:221-225.

    Not in our library10.1016/s1470-2045(00)00292-8

  233. 233.

    Rosén J., Lövgren A., Kogej T., Muresan S., Gottfries J., Backlund A. ChemGPS-NP Web: Chemical space navigation online. J. Comput. Aided Mol. Des. 2009;23:253-259.

    Not in our library10.1007/s10822-008-9255-y

  234. 234.

    Chemsketsh.

    Not in our library

  235. 235.

    Muigg P., Rosén J., Bohlin L., Backlund A. In silico comparison of marine, terrestrial and synthetic compounds using ChemGPS-NP for navigating chemical space. Phytochem. Rev. 2013;12:449-457.

    Not in our library10.1007/s11101-012-9256-2

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.